LBRX LB PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1691082 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-650.9%
TTM EPS YoY94.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-38.8%
ROA-36.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets7.9%
Debt / equity0.00x
Current ratio14.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $51.52M | $44.15M | $14.64M | $8.48M | $2.42M | $2.42M | $3.42M | $376,000 |
| SG&A expense | $10.98M | $9.77M | $7.46M | $5.39M | $2.83M | $2.44M | $3.01M | $5.16M |
| Pretax income | -$59.07M | -$51.60M | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.31M | -$5.07M |
| Income tax | $0 | $0 | $0 | $1,000 | $0 | $0 | $0 | $1,000 |
| Net income | -$59.07M | -$51.60M | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.31M | -$5.07M |
| EPS (basic) | -1.79 | -1.71 | -0.67 | — | -0.61 | -13.58 | -14.79 | — |
| EPS (diluted) | -1.79 | -1.71 | -0.67 | — | -0.61 | -13.58 | -14.79 | — |
| Weighted avg. shares (diluted) | 33.08M | 30.14M | 28.24M | — | 5.81M | 358,811 | 358,777 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $215.07M | $283.11M | $320.68M | $250.17M | $269.74M | — | — | $22.98M |
| Short-term investments | $188.69M | $44.68M | $44.96M | $45.04M | $44.73M | — | — | $5.02M |
| Current assets | $447.12M | $355.30M | $389.07M | $308.43M | $316.40M | — | — | $28.88M |
| PP&E, net | $2.15M | $2.20M | $1.53M | $1.58M | $1.64M | — | — | $1.86M |
| Total assets | $453.37M | $361.69M | $393.48M | $312.93M | $320.75M | — | — | $33.53M |
| Current liabilities | $30.25M | $23.56M | $10.91M | $7.44M | $6.65M | — | — | $8.11M |
| Total liabilities | $35.73M | $29.34M | $14.79M | $11.62M | $10.53M | — | — | $13.83M |
| Shareholders' equity | $417.64M | $332.35M | $378.69M | $301.31M | $310.22M | -$103.87M | -$99.34M | -$94.55M |
| Shares outstanding | 32.27M | 28.68M | 28.67M | 25.30M | 25.30M | — | — | 251,655 |
| Cash flow statement | ||||||||
| Operating cash flow | -$64.29M | -$37.63M | -$23.29M | -$18.10M | -$3.37M | -$5.60M | -$8.13M | -$5.67M |
| Capital expenditure | $70,000 | $363,000 | $32,000 | $40,000 | $0 | -$9,000 | $21,000 | $238,000 |
| Free cash flow | -$64.36M | -$37.99M | -$23.32M | -$18.14M | -$3.37M | -$5.59M | -$8.15M | -$5.90M |
| Investing cash flow | -$144.65M | $89,000 | -$32,000 | -$40,000 | -$44.84M | $9,000 | $4.98M | $13.54M |
| Financing cash flow | $140.92M | -$19,000 | $93.83M | -$1.17M | $303.73M | $0 | $0 | $0 |
| Depreciation & amortization | $124,000 | $97,000 | $82,000 | $85,000 | $81,000 | $76,000 | $79,000 | $80,000 |
| Stock-based compensation | $3.67M | $4.90M | $2.57M | $2.34M | $881,000 | $335,000 | $634,000 | $2.28M |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.